Plain-English translation of NCT05621837 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Melanoma research guide →This research study is testing whether measuring certain immune cells in your blood — specifically cells called myeloid-derived suppressor cells — can help doctors choose the best cancer treatment just for you. The study involves 1,000 patients with different types of advanced cancer who are already receiving standard treatments. By understanding how your immune system is working, researchers hope to improve how doctors pick and personalize your therapy.
Cancer can weaken the immune system in ways that doctors can't always see or predict. By measuring specific immune markers in your blood, this study aims to give doctors a better tool to understand your individual immune system and tailor treatment decisions accordingly — potentially improving outcomes for patients with melanoma, breast cancer, kidney cancer, bladder cancer, and lung cancer.
You likely qualify if…
You likely don't qualify if…
You will continue receiving your standard cancer treatment as planned. At certain visits, the study team will collect blood samples and ask you about your life experiences, including how socially connected you feel — information that may help researchers understand the link between isolation and immune function. You'll also allow researchers to use your existing tumor tissue sample for testing. The study team will follow your progress over time to see how the immune markers in your blood relate to how well your treatment works.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Italy
Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Enrollment target
~1,000 participants
Started
March 2022
Primary completion
December 2026
Age range
18 Years – 90 Years
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Licia Rivoltini
Fondazione IRCCS Istituto Nazionale Tumori - Milan
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.